ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development
ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, today announced a partnership in the development of customized biomarker assay solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and ARGO™ HT System. This collaboration aims to provide advanced tools for the detection and quantification of critical biomarkers to support neurological disease therapeutic development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027884281/en/
ADx NeuroSciences logo (Graphic: Business Wire)
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide tailored assay solutions to meet the specific needs of pharmaceutical companies advancing novel therapeutics for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS.
"We are excited to partner with ADx NeuroSciences, a recognized leader in the field of neurodegenerative biomarker research," said Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform's ultra-sensitive detection capabilities with ADx’s extensive expertise in neuroscience antibody and assay development, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease modifying therapies for neurodegenerative diseases.”
Koen Dewaele, CEO of ADx NeuroSciences, commented, "Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs. Every phase in the search for a therapeutic, from preclinical work up to the launch of the ultimate drug, requires specific biomarker tools. By working with various technology platforms, we are able to make our biomarker assays available on the right technology at the right time. By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers."
This strategic collaboration highlights both companies' commitment to advancing biomarker detection and expanding the possibilities for early diagnosis and treatment of neurodegenerative diseases. By harnessing the power of the NULISA platform, Alamar Biosciences and ADx NeuroSciences aim to deliver cutting-edge solutions that will benefit clinical research and aid in the development of novel therapeutics.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System works seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the high sensitivity protein detection technologies on the market today. For more information, please visit alamarbio.com.
About ADx NeuroSciences NV
ADx NeuroSciences is specialized in the research and development of neurodegenerative biomarker tools for diseases such as Alzheimer's and Parkinson's. Its expertise is used by pharmaceutical and diagnostic companies across the world for the conception, development, production, and worldwide commercialization of novel biomarkers, supporting the development of promising drugs, either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays can be applied to a variety of platforms from research up to IVD use. The company was founded in 2011 and was acquired in 2022 by Fujirebio, a member of H.U. Group Holdings Inc., which is listed on the Tokyo Stock Exchange (TSE: 4544). For more information, please visit www.adxneurosciences.com.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality IVD testing with more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers for AD testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. For more information, please visit www.fujirebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241027884281/en/
Contacts
For media inquiries, please contact:
Alamar Biosciences, Inc. Media Contact:
April Falcone
Alamar Biosciences
afalcone@alamarbio.com
(510) 838-1783
ADx NeuroSciences NV:
Ann De Vos
ADx NeuroSciences
info@adxneurosciences.com
+32 9 329 1486
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nakiki SE: Nakiki SE Evaluates Corporate Bond Offering for Strategic Bitcoin Investment27.8.2025 19:51:00 EEST | Press release
Nakiki SE is currently evaluating the issuance of a corporate bond with a target volume in the mid–single-digit million-euro range. As part of a pre-market sounding process, the Management Board is assessing interest from professional investors. The proceeds of the issuance are intended primarily for the acquisition of Bitcoin. Language: English Company: Nakiki SE Hanauer Landstr. 204 60314 Frankfurt on the Main Germany E-mail: info@nakikifinance.com Internet: https://nakikifinance.com/ ISIN: DE000WNDL300, DE000WNDL318 WKN: WNDL30, WNDL31 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange View source version on businesswire.com: https://www.businesswire.com/news/home/20250827593566/en/
Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm27.8.2025 18:30:00 EEST | Press release
Boomi™, the leader in AI-driven automation, today announced it has been named a Leader in The Forrester Wave™: Integration Platform As A Service, Q3 2025. The report evaluated the 10 most significant iPaaS vendors, and Boomi achieved the highest score in thestrategy category among all evaluated providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826324359/en/ Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm The report states that Boomi has reoriented with an “intense focus on AI and APIs,” “receives strong feedback from its partners,” and maintains “clear investment priorities.” Reference customers were impressed by the company’s level of investment in the product and its vision for the future, and look forward to seeing Boomi deliver on its AI roadmap. “We’re honored to be named a Leader in the Forrester Wave — and especially proud to receive the to
Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences27.8.2025 17:00:00 EEST | Press release
Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulatory writing by reducing variability and improving the quality, consistency, and speed of documentation. Evidence Matters’ RegulatoryFlow platform (“RegFlow”) and specialized services unify clinical data and documents, simplify workflows, and accelerate the work of key life sciences professionals, from medical writers to regulatory specialists. “We are excited to work alongside Evidence Matters to co-develop technology that directly enhances the quality and efficiency of regulatory writing,” said Nicole Maciolek, Vice President,
Andersen Consulting Adds Collaborating Firm Skribble27.8.2025 16:30:00 EEST | Press release
Andersen Consulting expands its strategy and business transformation capabilities through a Collaboration Agreement with Skribble, a digital and brand consultancy supporting innovation and operational transformation for companies in Southeast Asia. Established in 2020, Skribble offers a wide range of services, including brand and communications strategy, digital marketing, custom technology development, change management, and platform solutions. The firm supports organizations in real estate, consumer goods, banking, and government by aligning strategy with execution to deliver integrated brand, performance, and technology solutions. With a focus on process optimization and a full creative and technical skillset, Skribble helps clients drive transformation and growth. “At Skribble, we pride ourselves on translating creative energy into strategic outcomes,” said Chan Leong, CEO of Skribble. “We approach each client with precision and passion, applying deep market insight, sharp executio
Veridas Named a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification27.8.2025 15:34:00 EEST | Press release
Veridas, a global identity company, has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification, reinforcing its position among the top global IDV vendors. Founded in 2017 and operating globally, Veridas enters the report as one of the fastest-growing companies in the market. Gartner defines Visionaries as vendors that understand where the market is going or have a vision for changing market rules. This positioning validates Veridas’ long-term strategy and highlights its leadership in innovation, ethical design, and user-centric digital identity. At the core of Veridas’ approach is its 100% proprietary technology stack, covering facial biometrics, voice authentication, document verification, age validation, physical access control, and its ID Wallet. By developing all core technologies in-house, Veridas ensures full control over security, performance, and compliance, enabling end-to-end protection against fraud, higher user conversion rates, and gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom